Editas Deal Opens Allergan's Eyes To CRISPR Opportunities

 
• By Lucie Ellis-Taitt

Editas' stock shot up 11% by mid-morning on March 14, after the gene therapy company announced a deal with Allergan worth $90m up front for "cool" CRISPR programs in ocular indications. However, the lead therapy included in the deal offers potentially limited profitability in a small orphan space.

DNA detail background with selective focus
Allergan makes its first move into CRISPR gene editing via Editas deal • Source: Horizon Discovery

More from Business

More from Scrip